Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

SYNBIOTIC SE: subsidiary Hempro International applies for preliminary insolvency proceedings

Management of Hempro International has announced it will file an application with the Münster district court to open preliminary insolvency proceedings. The causes are a marked drop in demand and sales since March 2026 due to worsening economic conditions following geopolitical events. SYNBIOTIC SE is reconsidering the operational development of its subsidiaries as part of restructuring measures and will no longer continue financial support for Hempro; potential impacts on the balance sheet and results are being reviewed. » Plus sur finanzen.net
SynBiotic share plunges almost 20% after US cannabis reclassification

The SynBiotic share lost 14.4% in Xetra trading and fell a further almost 20% in after-hours trading. The trigger was the official initiation of a US reclassification of cannabis intended to make medical use easier but not to provide nationwide legalization for recreational purposes. Ahead of this, the stock had already benefited from speculation about a loosening of US rules. » Plus sur finanzen.net
Synbiotic shares more than double since Friday after anchor investor steps in

Synbiotic shares rose by more than 100% since Friday and continued on Wednesday with a gain of over 12% to 3.55 euros; intraday they reached up to 3.78 euros. Earlier in the week the papers had already climbed by as much as 42% after they had marked a record low near 1.50 euros last week. Analyst Harald Hof cited several positive triggers: two smaller capital increases, the insolvency of a non-core subsidiary, sector tailwinds and the entry of the hemp equity fund Cansoul as a new anchor investor in a cash capital increase. » Plus sur de.investing.com

Dividendes historiques Dividendes

Tous les indicateurs de dividendes Tous les indicateurs

En 2022, SynBiotic a déjà versé 0,30€ de dividendes. Le dernier versement a eu lieu en juillet 2022.

Données financières de l'entreprise

Au cours de la dernière année, SynBiotic a réalisé un chiffre d'affaires de 3.86m€ et un bénéfice net de −10.63m€

(EUR)	2023	YoY
Chiffre d'affaires	+3.86m	52,71%
Bénéfice brut	+1.51m	57,83%
Bénéfice net	−10.63m	56,36%
EBITDA	−7.12m	4,85%

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	+3.45m€
Nombre d'actions	4.75m
Plus haut/bas sur 52 semaines	+3,85€ - +0,50€
Dividendes	Non
Bêta	0,68
Ratio P/E	−0,32
Ratio PEG	0,00
Ratio P/B	+0,22
Ratio P/S	+0,89

Profil de l'entreprise

SynBiotic SE beschäftigt sich mit der Entwicklung von Medikamenten und rezeptfreien Wellness-Produkten auf der Basis von Cannabinoiden. Das Unternehmen konzentriert sich auf die synthetische Herstellung von Cannabinoiden, die Entwicklung von Medikamenten, Nahrungsergänzungsmitteln und kosmetischen Produkten. Das Unternehmen war früher als Ledgertech SE bekannt und änderte seinen Namen in Ledgertech SE. SynBiotic SE hat seinen Sitz in München, Deutschland.

Nom	SynBiotic
PDG	Daniel Kruse
Siège social	Düsseldorf, nw Allemagne
Site web	synbiotic.com/de
Secteur	Santé
Industrie	Biotechnologie
Introduction en bourse	07/01/2021
Employés	79